Edgewise Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Edgewise Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($40.67M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($36.12M) | Aug 7, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($36.12M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($40.80M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($40.80M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($40.80M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($34.13M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($31.50M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($31.50M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($28.53M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($28.53M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($28.53M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($25.71M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($21.47M) | Aug 8, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($21.47M) | Nov 7, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($22.84M) | Nov 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($22.84M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($22.84M) | Aug 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($17.50M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.07M) | Aug 10, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($46.86M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($42.61M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($45.96M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($40.43M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($38.11M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($34.75M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($29.45M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($25.34M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($25.70M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($18.26M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($16.49M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($14.83M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($13.08M) | Nov 3, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($10.46M) | Aug 4, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.86M) | May 11, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.64M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($3.96M) | Aug 9, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($3.25M) | May 13, 2021 |